



Sheet 1 of 1

SUBSTITUTE FORM PTO-144A (1-94) U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No. 01948/088004  Serial No. 10/624,809  Applicant Karumanchi et al.  Filing Date July 21, 2003  Group 1647  IDS Filed October 25, 2006
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
/I.D./	2006/0183175	August 17, 2006	Buhimschi et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
/I.D./	WO 2006/069373	June 29, 2006	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
/I.D./	Del-Sorbo et al., "The Synthesis of Platelet-Activating Factor Modulates Chemotaxis of Monocytes Induced by HIV-1 Tat," <i>Eur. J. Immunol.</i> 29:1513-1521 (1999).					
	Gordon et al., "Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients with Advanced Cancer," <i>J. Clin. Oncol.</i> 19:843-850 (2001).					
	Hunter et al., "Serum Levels of Vascular Endothelial Growth Factor in Preeclamptic and Normotensive Pregnancy," <i>Hypertension</i> 36:965-969 (2000).					
	Margolin et al., "Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination with Chemotherapy in Patients with Advanced Cancer: Pharmacologic and Long-Term Safety Data," <i>J. Clin. Oncol.</i> 19:851-856 (2001).					
↓	Sugimoto et al., "Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria," <i>J. Biol. Chem.</i> 278:12605-12608 (2003).					

EXAMINER	/Ian Dang/	DATE CONSIDERED	04/23/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			